Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Aimee Yu

Pulmonary Disease Annapolis, MD Medical Doctor

NPI 1982603940 CMS profile 270937

2000 Medical Pkwy, Suite 607, Annapolis, MD 21401

Open in the dashboard

General payments

$2,061

98 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Aimee Yu of Annapolis, MD is reported in the CMS Open Payments database as having received $2,061 across 98 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $701 39
2019 General $1,360 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aimee Yu
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Aimee Yu were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Aimee Yu Pulmonary Disease median Middle half National median
2019 $1,360 $377 $109–$1,340 $163
2020 $701 $230 $56–$907 $114
2021 $0 $269 $68–$1,072 $132
2022 $0 $390 $100–$1,457 $149
2023 $0 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $388 20 payments
  2. AstraZeneca Pharmaceuticals LP $361 17 payments
  3. Genzyme Corporation $276 8 payments
  4. GlaxoSmithKline, LLC. $232 12 payments
  5. Insmed, Inc. $156 11 payments
  6. Mallinckrodt Enterprises LLC $142 3 payments
  7. Grifols USA, LLC $98 5 payments
  8. Mylan Specialty L.P. $48 3 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $46 2 payments
  10. Philips Electronics North America Corporation $45 2 payments
  11. Other $269 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $2,061 98 payments
Products named General payments · program years 2019–2020
  1. OFEV $404 21 payments
  2. FASENRA $269 11 payments
  3. DUPIXENT $194 4 payments
  4. Arikayce $156 11 payments
  5. NUCALA $145 7 payments
  6. ACTHAR $142 3 payments
  7. SPIRIVA RESPIMAT $109 6 payments
  8. Prolastin-C Liquid $98 5 payments
  9. SYMBICORT $92 6 payments
  10. STIOLTO RESPIMAT $87 5 payments
  11. Other $668 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record